- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial | 99 | PR Newswire | Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced solid tumor... ► Artikel lesen | |
| Fr | Why Electro Optic Systems, Megaport, Racura, and Xero shares are racing higher today | 13 | The Motley Fool Australia | ||
| Fr | Daily Special: Racura Oncology, AVITA Medical, Archer Materials, Resolution Minerals | 9 | Finance News Network | ||
| RACURA ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| Fr | Racura Oncology Advances CPACS Trial to Next Dose Level | 1 | smallcaps.com.au | ||
| Fr | RACURA ONCOLOGY LTD: CPACS Trial Cleared to Escalate to Next RC220 Dose Level | - | ASX | ||
| Do | RACURA ONCOLOGY LTD: Appendix 3Y - Dr Daniel Tillett | - | ASX | ||
| Do | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 08.05. | RACURA ONCOLOGY LTD: Racura Oncology Options Expiry Reminder | - | ASX | ||
| 07.05. | RACURA ONCOLOGY LTD: Appendix 3Y - Dr Daniel Tillett | - | ASX | ||
| 07.05. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 04.05. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 30.04. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 29.04. | RACURA ONCOLOGY LTD: March 2026 Quarterly Activity Report and Appendix 4C | - | ASX | ||
| 29.04. | RACURA ONCOLOGY LTD: Racura and Wollongong Uni Granted NSW TechVoucher | - | ASX | ||
| 24.04. | RACURA ONCOLOGY LTD: Notification of cessation of securities - RAC | - | ASX | ||
| 23.04. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 22.04. | Racura Oncology Presents Key MYC Silencing Data at Major Cancer Conference | 1 | Finance News Network | ||
| 22.04. | RACURA ONCOLOGY LTD: Racura presents MYC silencing data at AACR 2026 | - | ASX | ||
| 16.04. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 09.04. | RACURA ONCOLOGY LTD: Racura Singapore and HK Investor Briefing Update | - | ASX |
1 2 3 4 5 Weiter >>
90 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IMMUNOVANT | 35,650 | +35,60 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| HCW BIOLOGICS | 2,490 | +134,91 % | HCW Biologics Inc.: HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results | MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,760 | +12,05 % | H.C. Wainwright Reduced its Price Goal on Summit Therapeutics Inc. (SMMT) | ||
| QIAGEN | 29,910 | +0,66 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| RELAY THERAPEUTICS | 12,955 | +7,33 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies | Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing Interim investigator- and patient-reported... ► Artikel lesen | |
| METAVIA | 2,940 | +56,38 % | MetaVia Inc.: MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update | 48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit
Key Milestone... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,000 | +3,45 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 335,74 | +4,72 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| ERASCA | 11,090 | +7,46 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,930 | +5,38 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results | - Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 36,850 | +2,70 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 81,22 | +3,76 % | Jefferies raises Apogee Therapeutics stock price target on trial outlook | ||
| BEAM THERAPEUTICS | 27,230 | +3,42 % | Beam Therapeutics presents AATD gene therapy trial data at ATS | ||
| CG ONCOLOGY | 65,04 | +2,75 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 28,340 | +8,87 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) |
RACURA ONCOLOGY LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,440 Euro und damit -2,04 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RACURA ONCOLOGY LTD finden Sie auf Wallstreet Online.